Published in
Impact Journals, Oncotarget, 7(5), p. 1846-1855, 2014
Links
- ORCID
- Impact Journals
- ORCID
- [www.ncbi.nlm.nih.gov] | PDF
- [www.researchgate.net] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [europepmc.org] | PDF
Tools
Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus
Journal article published in 2014 by
Sarina A. Piha-Paul 
,
Jennifer J. Wheler,
Siqing Fu ,
Charles Levenback,
Karen Lu,
Gerald S. Falchook,
Aung Naing,
David S. Hong,
Apostolia M. Tsimberidou,
Razelle Kurzrock
,
Jennifer J. Wheler,
Siqing Fu ,
Charles Levenback,
Karen Lu,
Gerald S. Falchook,
Aung Naing,
David S. Hong,
Apostolia M. Tsimberidou,
Razelle Kurzrock
This paper is made freely available by the publisher.
Full text: Download
Preprint: archiving forbidden
Postprint:
archiving forbidden
Data provided by 
Abstract
Background: Bevacizumab and temsirolimus are active agents in gynecologic tumors. Temsirolimus attenuates upregulation of HIF-1α levels, a resistance mechanism for antiangiogenics, and targets the PI3-kinase/AKT/mTOR axis, commonly aberrant in these tumors